CytoSorbents Awarded $203K Phase I SBIR Contract from NHLBI/NIH for HemoDefend(TM)

CytoSorbents Awarded $203K Phase I SBIR Contract from NHLBI/NIH for 
HemoDefend(TM) 
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 09/09/13 --  CytoSorbents
Corporation (OTCBB: CTSO), a critical care focused company
specializing in blood purification, announced today that the National
Heart, Lung, and Blood Institute (NHLBI), a division of the National
Institutes of Health (NIH), awarded the Company a Phase I SBIR (Small
Business Innovation Research) contract to further advance its
HemoDefend(TM) blood purification technology for packed red blood
cell (pRBC) transfusions. The project, entitled "Elimination of blood
contaminants from pRBCs using HemoDefend hemocompatible porous
polymer beads," is valued at $203,351 over 6 months, with funding to
start immediately.  
The overall goal of this new program is to reduce the risk of
potential side effects of blood transfusions, and help to extend the
useful life of pRBCs. The HemoDefend(TM) platform is based upon
CytoSorbents' proprietary hemocompatible porous polymer bead
technology and already removes many blood contaminants that can
potentially cause transfusion reactions such as free hemoglobin,
antibodies, and cytokines. Funding will expand the platform to remove
an even broader range of blood contaminants, assess the quality of
the blood after treatment, and facilitate the parallel development of
the HemoDefend(TM) In-line filter, designed to be used at the patient
bedside to purify existing blood products, and the unique
HemoDefend(TM) "Beads-in-a-Bag" blood treatment bag, intended to
replace current simple blood storage bags.  
As part of this program, CytoSorbents will be collaborating with Dr.
Larry J. Dumont, MBA, PhD, Director of the Center for Transfusion
Medicine Research and Associate Professor of Pathology at the Geisel
School of Medicine at Dartmouth. 
Dr. Dumont stated, "Transfusion medicine has made great strides in
improving the quality and safety of the blood supply, though many
risks remain. CytoSorbents' innovative HemoDefend(TM) technology
could represent a significant advance in reducing contaminants in
blood transfusion products that may lead to transfusion reactions and
adverse clinical events. We look forward to working closely with
CytoSorbents in further developing this exciting new technology."  
Chief Executive Officer, Dr. Phillip Chan, MD, PhD stated, "We thank
NHLBI and Dr. Dumont for their support of our HemoDefend(TM)
platform. Success of this Phase I program may accelerate
commercialization of our HemoDefend products, facilitate ongoing
discussions with potential partners, and lead to further funding and
development via larger Phase II and III SBIR awards. With an
estimated 85 million pRBC transfusions worldwide each year, hundreds
of thousands of related adverse events, and ongoing clinical studies
such as RECESS and ABLE that may show the risk of older blood, we
believe that HemoDefend(TM) has significant commercial potential."  
HemoDefend(TM) is under advanced development and is not yet approved
in the U.S. or elsewhere. This project has been funded in whole or in
part with Federal funds from the National Heart, Lung, and Blood
Institute, National Institutes of Health, Department of Health and
Human Services, under Contract No. HHSN268201300044C.  
About the National Heart, Lung, and Blood Institute 
The NHLBI provides global leadership for a research, training, and
education program to promote the prevention and treatment of heart,
lung, and blood diseases and enhance the health of all individuals so
that they can live longer and more fulfilling lives. The NHLBI
supports research on the use, safety, and availability of blood and
blood components for transfusion and cellular therapies. The NHLBI
stimulates basic discoveries about the causes of disease, enables the
translation of basic discoveries into clinical practice, fosters
training and mentoring of emerging scientists and physicians, and
communicates research advances to the public. It creates and supports
a robust, collaborative research infrastructure in partnership with
private and public organizations, including academic institutions,
industry, and other government agencies. The Institute collaborates
with patients, families, health care professionals, scientists,
professional societies, patient advocacy groups, community
organizations, and the media to promote the application of research
results and leverage resources to address public health needs. The
NHLBI also collaborates with international organizations to help
reduce the burden of heart, lung, and blood diseases worldwide.  
About CytoSorbents Corporation 
CytoSorbents Corporation is a critical care focused therapeutic
device company that specializes in blood and biological fluid
purification. Its purification technology is based on biocompatible,
highly porous polymer beads that can actively remove toxic substances
from blood and other bodily fluids by pore capture and adsorption.
Some of the Company's products include: 


 
--  CytoSorb(R) - The Company's flagship product is approved and sold
    in the European Union as a safe and effective cytokine blood filter,
    with the goal of preventing or treating organ failure -- the leading
    cause of death in the intensive care unit with no effective therapies
    -- in life threatening illnesses such as sepsis, burn injury, trauma,
    lung injury, pancreatitis, and many others. A major unmet medical
    need, organ failure costs millions of lives, and billions of dollars
    each year. Development of the next generation of CytoSorb(R) is
    being partially funded by DARPA and the US Army.
--  HemoDefend(TM) - Currently under advanced development, this
    technology is designed to remove non-infectious contaminants in blood
    transfusion products, such as free hemoglobin, cytokines, bioactive
    lipids, and antibodies, which may significantly contribute to the
    transfusion reactions and adverse outcomes of blood transfusions.
--  ContrastSorb - A development-stage technology designed to rapidly
    remove intravenous (IV) imaging contrast from blood that could
    otherwise cause kidney failure, or contrast-induced nephropathy, in
    high risk patients undergoing the millions of interventional radiology
    procedures, such as cardiac catheterizations, and imaging CT scans
    with IV contrast each year.
--  DrugSorb - Is a development-stage product designed to remove drugs,
    chemotherapy agents, and other chemicals from blood in drug overdose,
    high dose regional chemotherapy, chemical poisoning, and other
    applications.

  
Additional information is available on the Company's website:
http://www.cytosorbents.com. 
Forward-Looking Statements 
This press release includes forward-looking statements intended to
qualify for the safe harbor from liability established by the Private
Securities Litigation Reform Act of 1995. Forward-looking statements
in this press release are not promises or guarantees and are subject
to risks and uncertainties that could cause our actual results to
differ materially from those anticipated. These statements are based
on management's current expectations and assumptions and are
naturally subject to uncertainty and changes in circumstances. We
caution you not to place undue reliance upon any such forward-looking
statements. Actual results may differ materially from those expressed
or implied by the statements herein. CytoSorbents Corporation and
CytoSorbents, Inc believe that its primary risk factors include, but
are not limited to: obtaining government regulatory approvals;
ability to successfully develop commercial operations; dependence on
key personnel; acceptance of the Company's medical devices in the
marketplace; the outcome of potential litigation; compliance with
governmental regulations; reliance on research and testing facilities
of various universities and institutions; the ability to obtain
adequate and timely financing in the future when needed; product
liability risks; limited manufacturing experience; limited marketing,
sales and distribution experience; market acceptance of the Company's
products; competition; unexpected changes in technologies and
technological advances; and other factors detailed in the Company's
Form 10-K filed with the SEC on April 3, 2013, which is available at
http://www.sec.gov 
Company Contact:
CytoSorbents Corporation
Dr. Phillip Chan
Chief Executive Officer
(732) 329-8885 ext. *823
pchan@cytosorbents.com 
Investor Contact:
Alliance Advisors, LLC
Alan Sheinwald
(914) 669-0222
asheinwald@allianceadvisors.net 
Valter Pinto
(914) 669-0222 x201
valter@allianceadvisors.net 
Media Contact:
JQA Partners
Jules Abraham
(917) 885-7378
jabraham@jqapartners.com 
 
 
Press spacebar to pause and continue. Press esc to stop.